Literature DB >> 15215088

Cloning of S-adenosyl-L-methionine:C-24-Delta-sterol-methyltransferase (ERG6) from Leishmania donovani and characterization of mRNAs in wild-type and amphotericin B-Resistant promastigotes.

Mohammad Pourshafie1, Stanislas Morand, Alain Virion, Michaelle Rakotomanga, Corinne Dupuy, Philippe M Loiseau.   

Abstract

The 24-alkylated sterols have been shown previously to be absent in membranes of amphotericin B (AmB)-resistant Leishmania donovani promastigotes, suggesting that the S- adenosyl-l-methionine:C-24-Delta-sterol-methyltransferase (SCMT or ERG6) was not functional or not expressed in AmB-resistant (AmB-R) parasites. From an L. donovani wild-type clone, we cloned two cDNAs with an identical open reading frame encoding a putative SCMT, the enzyme responsible for a first sterol methylation at the C-24 position. The two cDNAs differed by their 3'-untranslated region (3'-UTR) and 5'-UTR sequences. One transcript (A) had a normal structure with a spliced leader and was highly expressed in normal cells but absent in AmB-R cells. The other (B), which did not possess the spliced leader sequence, was weakly expressed in normal cells but strongly expressed in AmB-R cells. As a functional test, ERG6 null mutant Saccharomyces cerevisiae yeasts were transformed using the pYES2.1 TOPO TA expression vector containing the candidate SCMT1/ERG6 coding sequence cloned from L. donovani. The transformed yeasts exhibited C-24 alkylated sterol expression, mainly ergosterol, within their membranes, proving that the isolated cDNA encodes on a SCMT responsible for sterol methylation. In AmB-R L. donovani promastigotes, the absence of the normal transcript (A) and the expression of an abnormal species (B) devoid of a spliced leader could explain the absence of sterol methylation in these cells. Further studies using a homologous system will allow us to draw conclusions about the relationship between SCMT expression and AmB resistance in Leishmania.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15215088      PMCID: PMC434211          DOI: 10.1128/AAC.48.7.2409-2414.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  22 in total

Review 1.  Treatment of visceral leishmaniasis (kala-azar): a decade of progress and future approaches.

Authors:  H W Murray
Journal:  Int J Infect Dis       Date:  2000       Impact factor: 3.623

2.  Gene amplification in amphotericin B-resistant Leishmania tarentolae.

Authors:  A K Singh; B Papadopoulou; M Ouellette
Journal:  Exp Parasitol       Date:  2001-11       Impact factor: 2.011

Review 3.  Amphotericin B: spectrum and resistance.

Authors:  David Ellis
Journal:  J Antimicrob Chemother       Date:  2002-02       Impact factor: 5.790

Review 4.  Chemotherapy of leishmaniasis.

Authors:  Simon L Croft; Vanessa Yardley
Journal:  Curr Pharm Des       Date:  2002       Impact factor: 3.116

Review 5.  Promising therapeutic targets for antileishmanial drugs.

Authors:  Karl A Werbovetz
Journal:  Expert Opin Ther Targets       Date:  2002-08       Impact factor: 6.902

6.  High efficiency plating method for Leishmania promastigotes in semidefined or completely-defined medium.

Authors:  D M Iovannisci; B Ullman
Journal:  J Parasitol       Date:  1983-08       Impact factor: 1.276

7.  DEVELOPMENT OF RESISTANCE TO POLYENE ANTIBIOTICS IN CANDIDA ALBICANS.

Authors:  E K HEBEKA; M SOLOTOROVSKY
Journal:  J Bacteriol       Date:  1965-06       Impact factor: 3.490

8.  Transformation of intact yeast cells treated with alkali cations.

Authors:  H Ito; Y Fukuda; K Murata; A Kimura
Journal:  J Bacteriol       Date:  1983-01       Impact factor: 3.490

9.  Requirement for a second sterol biosynthetic mutation for viability of a sterol C-14 demethylation defect in Saccharomyces cerevisiae.

Authors:  F R Taylor; R J Rodriguez; L W Parks
Journal:  J Bacteriol       Date:  1983-07       Impact factor: 3.490

10.  Incidence of polyene-resistant yeasts recovered from clinical specimens.

Authors:  J D Dick; W G Merz; R Saral
Journal:  Antimicrob Agents Chemother       Date:  1980-07       Impact factor: 5.191

View more
  28 in total

1.  Mechanism of amphotericin B resistance in clinical isolates of Leishmania donovani.

Authors:  Bidyut Purkait; Ashish Kumar; Nilay Nandi; Abul Hasan Sardar; Sushmita Das; Sudeep Kumar; Krishna Pandey; Vidyananda Ravidas; Manish Kumar; Tripti De; Dharmendra Singh; Pradeep Das
Journal:  Antimicrob Agents Chemother       Date:  2011-11-28       Impact factor: 5.191

2.  In vitro and in vivo interactions between miltefosine and other antileishmanial drugs.

Authors:  Karin Seifert; Simon L Croft
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

3.  Leishmania infantum sterol 24-c-methyltransferase formulated with MPL-SE induces cross-protection against L. major infection.

Authors:  Yasuyuki Goto; Ajay Bhatia; Vanitha S Raman; Silvia E Z Vidal; Sylvie Bertholet; Rhea N Coler; Randall F Howard; Steven G Reed
Journal:  Vaccine       Date:  2009-03-09       Impact factor: 3.641

Review 4.  Drug resistance in leishmaniasis.

Authors:  Simon L Croft; Shyam Sundar; Alan H Fairlamb
Journal:  Clin Microbiol Rev       Date:  2006-01       Impact factor: 26.132

5.  Protective immunization against visceral leishmaniasis using Leishmania sterol 24-c-methyltransferase formulated in adjuvant.

Authors:  Yasuyuki Goto; Lisa Y Bogatzki; Sylvie Bertholet; Rhea N Coler; Steven G Reed
Journal:  Vaccine       Date:  2007-08-20       Impact factor: 3.641

6.  Sterol methyltransferase is required for optimal mitochondrial function and virulence in Leishmania major.

Authors:  Sumit Mukherjee; Wei Xu; Fong-Fu Hsu; Jigesh Patel; Juyang Huang; Kai Zhang
Journal:  Mol Microbiol       Date:  2018-10-21       Impact factor: 3.501

7.  Production and characterization of stable amphotericin-resistant amastigotes and promastigotes of Leishmania mexicana.

Authors:  Hamdan I Al-Mohammed; Michael L Chance; Paul A Bates
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

8.  Miltefosine affects lipid metabolism in Leishmania donovani promastigotes.

Authors:  M Rakotomanga; S Blanc; K Gaudin; P Chaminade; P M Loiseau
Journal:  Antimicrob Agents Chemother       Date:  2007-01-22       Impact factor: 5.191

9.  Drug resistance in leishmaniasis.

Authors:  Jaya Chakravarty; Shyam Sundar
Journal:  J Glob Infect Dis       Date:  2010-05

10.  Immunoadjuvant chemotherapy of visceral leishmaniasis in hamsters using amphotericin B-encapsulated nanoemulsion template-based chitosan nanocapsules.

Authors:  Shalini Asthana; Anil K Jaiswal; Pramod K Gupta; Vivek K Pawar; Anuradha Dube; Manish K Chourasia
Journal:  Antimicrob Agents Chemother       Date:  2013-01-28       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.